1. Прилепская В.Н. Пролонгированная контрацепция – новый подход к решению женских проблем. Гинекология. 2005; 7 (4): 224–6.
2. Andrist LC, Hoyt J, Weinstein D, McGibbon C. The need to bleed: women's attitudes and beliefs about menstrual suppression. J Am Acad Nurse Pract 2004; 16 (1): 31–7.
3. ARHP/NPWH. Obstacles to using extended contraceptive regimens. Clin Proc 2003; (April): l 1–2.
4. Association of Reproductive Health Professionals. Choosing when to menstruate: the role of extended contraception. Retrieved April 21, 2004 from http://arhphoru/healthcareprovidcrs/visitiimfacultvprograms/extended national surver, dm: 2002.
5. Back DJ, Breckenridge АМ, Crawford F еt al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21: 46–61.
6. Back DJ, Grimmer SFM, Оrmе MLE еt al. Evaluation оf committee оn safety of medicines yellow card reports оn оrаl contraceptive-drug interactions with anticonvulsants and antibiotics. Вг J Clin Pharmacol 1988; 25: 527–32.
7. Back DJ, Оrmе MLE. Pharmacokinetic drag interactions with огаl contraceptives. Clin Pharmacokinetic 1990; 18: 472–84.
8. Birkhauser М, Braendle W, Breckwoldt М et al. 24th Workshop of the 'Zurcher Gesprachskreis' Мау 2000: recommendations оn оrаl contraception. Frauenarzt 2000; 41: 1053–8.
9. Blanchard K. Life without menstruation. The Obstetrician Gynecologist 2003; 5: 34–7.
10. Bloemenkamp KWM, Rosendaal FR, Bueller HR et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65–70.
11. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM et al Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects Arch Intern Med 2000; 160: 49–52.
12. Bunion LA, Vessey MP, Flavel R et al. Risk factors for benign breast disease Am J Epidemiol 1981; 113: 203–14.
13. Contraceptive Method Mix. Guidlines for policy and service delivery. Geneva: WHO, 1994.
14. Coutinho EM, de Souza JC, Csapo AI. Reversible sterility induced by medroxyprogesterone injections. Fertil Steril 1966; 17: 261–6.
15. D'Аrсу PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986; 20: 353–62.
16. Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives Curr Womens Health Rep 2002; 2: 434–8.
17. Eraser IS, Jаnsеn RPS. Why do inаdvеrtеnt prеgnаnсiеs оcсur in оrаl contraceptive users? Еffеcсtivеnеss оf оrаl соntrаcерtivе rеgimеns and intеrfеring factors. Соntrаcерtiоn 1983; 27: 531–51.
18. Farrow A, Hull MGR, Northstone K, et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002; 10: 2754–61.
19. Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol 1990; 163: 2153–9.
20. Friedman AJ, Thomas РР. Does low -dose combination оrаl contraceptive use affect uterine size оf menstrual flow in premenopausal women with leiomyomata Obstet Gуnеcоl 1995; 85: 631–5.
21. Goldzieher J. Personal communication, 2003.
22. Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; 12 (Suppl.): S35–43.
23. Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestins contained in oral contraceptives. Contraception 1989; 40: 299–312.
24. Jung-Ноffmаnn С, Heidt F, Kuhl Н. Effect of two оrаl contraceptives containing 30 mkg ethinylestradiol and 75 mkg gestodene оr 150 (mkg desogestrel upоn various hormonal parameters. Соntrаcерtiоn 1998; 38: 593–603.
25. Killick SR, Bancroft К, Oelbaum S еt al. Еxtеnding the duration of the pill-free interval during combined оrаl contraception. Adv Contracept 1990; 6: 33–40.
26. Kistner RW. Use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 1956; 75: 264–78.
27. Klein BEK, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diab Carc 1990; 13: 895–8.
28. Kuhl H, Jung-Hoffmann C. Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 mkg ethinylestradiol and 150 mkg desogestrel Contraception 1988; 38: 381–90.
29. Kuhl Н, Gаhn G, Romberg G el al. А randоmizеd cross-over соmpаrisоn of two low-dose оrаl contraceptives upоn hоrmоnаl аnd metabolic parameters. 1: effects оn sexual hоrmоnе levels. Сontrаcерtiоn 1985; 31: 583–93.
30. Loudon NB, I-o/well M, Potta DM et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation, fhe tri-cucle regimen. BMJ 1997; 2: 487–90.
31. Loudon NB, Foxwell M, Potts DM et al. Acceptability of an oral contraceptive that reduse the frequency of menstruation: the tricycle regimen. Br Med 1997; 2: 487–90.
32. Marshall LM, Spiegelman D, Goldman МВ еt al. А prospective study of reproductive factors and oral contraceptive use in relation оn the risk оf uterine leiomyomata. Fertil Steril 1998; 70: 432–9.
33. Milan R Hencel. Mary Lake Poulan. Journal of Reproductive Medicine 2004; 49: 162–74.
34. Miller L, Hughes JP. Cоntinuоus combination оrаl contraceptive pills to eliminate withdrawal bIeeding: а randomized trial. Obstet Gуnеcоl 2003; 101: 653–61, 70.
35. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 2003; 362: 419–27, 52.
36. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9.
37. Molloy ВG, Соulsоn КА, Lee JM еt al. 'Missed pill' conception: fасt оr fiction? ВМJ 1985; 290: 1474–5.
38. National womens health network statement on using an extended cycle of oral contraceptives for menstrual suppressions.[Seasonale]. Retrieved January 14, 2004.
39. Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70: 229–40, 65.
40. Parazzini F, Ferraroni М, Bocciolone L еt al. Contraceptive mеthods and risk of pelvic endometriosis. Contraception 1994; 49: 47–55.
41. Park BK, Kitteringham NR, Рirmоhаmеd М еt al. Relevance of induction of human drag-metabolizing enzymes: pharmacological and toxicological implications. Вr J Pharmacol 1996; 41: 477–91.
42. Percival-Smith RKL, Frohlich J, Jones WN, Abercrombie BA. Lipid and lipoprotein changes during the seven days of oral contraception in women using two triphasic preparations. Contraception 1989; 38: 19–26.
43. Ramos R, Apelo R, Osteria T, Vilar E. A comparative analysis of three different dose combinations of oral contraceptives. Contraception 1989; 39: 165–77.
44. Rosendaal FR Thrombosis in the young epidemiology and risk factors A focus on venous thrombosis. Thrombos Haemost 1997; 78: 1–6.
45. Ruchhoft Е, Elkind-Hirsch КЕ, Malinak R. Pituitary function is altered during the same cycle in women with polycystic оyаrу syndrome treated with continuous оf cyclic оrаl contraceptives оf а gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60.
46. Rutter W, Knight C, Vizzard J et al. Womens attitude to withdrawal bleeding and theirt knowledge and beliefs about oral contraceptive pill. Med J Austr 1988; 149: 417–9.
47. Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291–4.
48. Spona J, Elstein М, Feichtinger W еt al. Shorter pill-free itnterval in combined оrаl contraceptives decreases follicular development. Contraception 1996; 54: 71–7.
49. Stanford JL, Brinton LA, Berman ML et al. Oral contraceptives and endometrial cancer, do other risk factors modify the association? Int J Cancer 1993; 54: 243–8.
50. Strassman BI. The evolution of endometrial cycles and menstruation. Q Rev Biol 1996; 71: 181–220.
51. Sulak P, Scow RD, Precce C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
52. Sulak PJ, Kuehl TJ, Ortiz M et al. Acceptance of altering the standart 21-day/7-day oral contraceprive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet 2002; 186: 1142.
53. Sulak PJ, Cressman ВЕ, Waldrop Е еt al. Extending the duration of active оrаl contraceptive pil1s to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83.
54. Sullivan Н, Furniss Н, Sроnа J et al. Effect of 21-day and 24-day oral contraceptive regimens containing gеstоdеnе (60 mkg) and ethinylestradiol (l5mkg) оn ovarian activity. Fertil Steri1 1999; 72: 115–20.
55. Svemdottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13.
56. Tonkelarr I, Oddens B. Preffered frequency and characteristic of menstrual bleeding in relation to reproductive status? oral contraceptive use? and hormone replacement therapy use. Contraception 1999; 59: 357–62.
57. Vercellini Р, Dе Giorgi О, Mosconi Р еt al. Cyproterone acetate versus а continuous monophasic оrаl contraceptive in the treatment of recurrent! pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52–61.
58. Wang E, Shi S, Cekan SZ et al. Hormonal consequences of'missing the pill' Соntrаcерtiоn 1982; 26: 545–66.
59. Wiegratz Inka, Herbert Kuhl. Drugs 2004; 64 (21).
60. Wiegratz L, Hummel HH, Zimmermann T et al Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives Contraception 2004; 69: 37–42.
61. World Health Organization Task Force on long-acting systemic agents for fertility regulation: a multicenter phase III comparative clinical trial of depot-medroxyprogesterone acetate given three monthly at doses of 100 mg or 150 mg. Contraceptive efficacy and side effects. Contraception 1986; 34: 223–35.

В.Н.Прилепская, Е.С.Чернышова

ГУ Научный центр акушерства, гинекологии и перинатологии (дир. – акад. РАМН, проф. В.И.Кулаков) РАМН, Москва